Welcome to our dedicated page for Bluebird Bio news (Ticker: BLUE), a resource for investors and traders seeking the latest updates and insights on Bluebird Bio stock.
This page aggregates historical BLUE (bluebird bio, Inc.) news, capturing the company’s evolution as a commercial-stage gene therapy business and its transition from a public to a private company. Founded in 2010 and headquartered in Somerville, Massachusetts, bluebird bio describes itself as having set the standard for gene therapy for more than a decade, with FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
News items for BLUE include corporate and transaction announcements, such as the February 21, 2025 definitive agreement to be acquired and taken private by funds managed by Carlyle and SK Capital, subsequent updates on the tender offer, regulatory approvals, and the June 2, 2025 announcement that the sale had closed and that bluebird’s common stock had ceased trading and would no longer be publicly listed.
In addition to deal-related coverage, bluebird’s releases provide context on its gene therapy platform, including references to its ex-vivo gene therapy data set, three FDA-approved therapies, and focus on access for patients, providers, and payers. Communications also highlight the company’s emphasis on safety analytics for lentiviral vector technologies and its work to expand manufacturing capacity and support treatment centers.
Investors, researchers, and industry observers can use this BLUE news feed to review the timeline of strategic decisions, financing events, and ownership changes that shaped bluebird bio’s path, as well as the company’s own description of its role in gene therapy for severe genetic diseases. Bookmark this page to quickly reference past press releases and transaction milestones associated with the former NASDAQ-listed ticker BLUE.
bluebird bio (Nasdaq: BLUE) has completed the restatement of its financial statements for 2022 and the first three quarters of 2022 and 2023. The company has filed its 2023 Form 10-K and Q1 2024 Form 10-Q with the SEC. The restatement was related to the identification of leases and treatment of non-lease components in lease agreements. Importantly, the restatement had no impact on the company's cash position or revenue. However, bluebird bio is delayed in filing its Q2 2024 Form 10-Q and is working to complete this filing as quickly as possible.
bluebird bio (Nasdaq: BLUE) has announced its participation in two upcoming investor conferences in September. The company's management team will engage in fireside chats at the following events:
1. 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, at 12:45 p.m. ET at the Encore Boston Harbor, Everett, MA.
2. Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 5:35 p.m. ET at the New York Marriott Marquis, New York, NY.
Investors can access live webcasts of these fireside chats through the 'Events & Presentations' page on bluebird bio's website. Replays will be available for 90 days following the events.
bluebird bio (Nasdaq: BLUE) received notices from Nasdaq on August 20, 2024, stating non-compliance with Listing Rule 5250(c)(1) due to delayed filing of Q1 and Q2 2024 Form 10-Qs. This follows a previous non-compliance notice for the delayed 2023 Form 10-K. The company must submit an updated compliance plan by September 4, 2024, and file all outstanding reports by October 14, 2024. BLUE announced on March 26, 2024, that it will restate financial statements for 2022 and the first three quarters of 2022 and 2023. The notices do not immediately affect BLUE's Nasdaq listing or stock trading. The company is working to complete these filings promptly.
bluebird bio (NASDAQ: BLUE) reported Q2 2024 results, highlighting 27 patient starts across its gene therapy portfolio. The company anticipates approximately 85 patient starts for 2024, with LYFGENIA launches accelerating in H2. Q2 net revenue was $16.1 million, up from $6.9 million in Q2 2023. Cash runway extends into Q2 2025.
Commercial progress includes favorable coverage for LYFGENIA, with over half of Medicaid-insured sickle cell patients in states affirming coverage. The company has activated 70+ Qualified Treatment Centers for LYFGENIA and ZYNTEGLO. bluebird expects 20-25% gross-to-net discounts across products in 2024.
James Sterling joined as CFO, and Michael Cloonan was appointed to the Board of Directors. The company is working to complete financial restatements for 2022 and 2023.
bluebird bio (Nasdaq: BLUE) has announced its upcoming conference call to discuss second quarter 2024 results and business updates. The call is scheduled for August 14, at 8:00 a.m. ET. Investors and interested parties can participate by dialing +1 (800) 715-9871 (U.S. and Canada) and providing the Conference ID 2776050. A live webcast will be available on the company's investor relations website, with a replay accessible for 90 days following the event. This announcement indicates that bluebird bio is preparing to share its financial performance and operational progress for Q2 2024, which could potentially impact the company's stock price based on the reported results and future outlook.
bluebird bio (Nasdaq: BLUE) has announced an inducement grant of stock options to its new controller and vice president of accounting, Joe Ewer. The Compensation Committee approved options to purchase 38,200 shares of common stock, with a grant date of August 1, 2024. The options have an exercise price of $1.08 per share, equal to the fair market value on the grant date. These options vest over four years, with 25% vesting after one year and the remainder vesting monthly. The options have a 10-year term and were granted as an inducement for Mr. Ewer's employment, in accordance with NASDAQ Listing Rule 5635(c)(4).
Bluebird bio (Nasdaq: BLUE) announced the approval of an inducement grant of 300,000 stock options to its new CFO, James Sterling. This grant, approved by the Compensation Committee, is in line with Nasdaq Listing Rule 5635(c)(4) and has a grant date of July 1, 2024. The options are priced at $0.98 per share, reflecting the market value on the grant date. The vesting schedule spans four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on Mr. Sterling's continued employment. These options have a 10-year term.
2Flo Ventures announces the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy. She has nearly two decades of experience in the biopharmaceutical industry, including roles at Chinook Therapeutics and Otsuka Pharmaceuticals. Dr. Jones-Burton's achievements include a $3.2 billion acquisition by Novartis and multiple industry awards. Her appointment aims to enhance 2Flo's portfolio, which includes companies like Cancer IQ and Vivacelle Bio. Dr. Jones-Burton's expertise aligns with 2Flo's mission of advancing health equity and supporting innovative healthcare solutions.
bluebird bio has appointed O. James Sterling as its new Chief Financial Officer (CFO), effective June 10, 2024. Sterling, who previously served as CFO at Renalytix plc, brings extensive experience in healthcare and capital markets. He succeeds Chris Krawtschuk, who played a pivotal role in improving the company's cash flow and financial stability. Sterling's appointment comes as bluebird bio faces the task of restating its financial statements for 2022 and 2023, which will delay its 2023 Annual Report and Q1 2024 Form 10-Q filings. This restatement is not expected to affect the company’s cash or revenue.
bluebird bio, Inc. (NASDAQ: BLUE) reported strong first quarter 2024 results with a net revenue of $18.6 million. The company anticipates a total of 85 to 105 patient starts for its FDA approved therapies in 2024. Despite a delay in filing financial statements due to a restatement, bluebird bio remains confident in its financial position.
FAQ
What is the current stock price of Bluebird Bio (BLUE)?
What is the market cap of Bluebird Bio (BLUE)?
